Aquestive Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AQST Nasdaq 2834 www.aquestive.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aquestive Therapeutics, Inc.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Apr 9th, 2026 7:00 am
Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3 - Mar 31st, 2026 5:34 am
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film - Mar 30th, 2026 5:00 am
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer - Mar 20th, 2026 5:00 am
Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data - Mar 11th, 2026 12:04 am
Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink Conf - Mar 10th, 2026 12:02 am
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - Mar 9th, 2026 2:01 pm
Aquestive Therapeutics Q4 Earnings Call Highlights - Mar 5th, 2026 4:47 pm
Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... - Mar 5th, 2026 12:01 pm
Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary - Mar 5th, 2026 6:30 am
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Mar 4th, 2026 4:30 pm
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates - Mar 4th, 2026 3:15 pm
Aquestive Therapeutics: Q4 Earnings Snapshot - Mar 4th, 2026 2:25 pm
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Mar 4th, 2026 2:01 pm
Harrow (HROW) Misses Q4 Earnings Estimates - Mar 2nd, 2026 4:00 pm
Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference - Feb 26th, 2026 1:48 pm
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences - Feb 25th, 2026 5:00 am
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET - Feb 24th, 2026 5:00 am
Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay - Feb 23rd, 2026 2:33 pm
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 23rd, 2026 5:00 am